Anto Biosciences, Inc.

Anto Biosciences, based in the United States, focuses on developing innovative multimodal models that enhance drug efficacy prediction by analyzing the gut microbiome's influence on pharmacology. Founded in 2025, Anto Biosciences, Inc. operates from San Francisco, US, providing advanced solutions for drug development through computational models. The company has conducted one deal as of December 19, 2025, but further details about its operational pivots or partnerships are not documented.

Anto Biosciences specializes in creating a multimodal foundation model that computes the gut microbiome, aiming to predict drug toxicity and efficacy. By integrating various data types and minimizing noise, their technology enhances drug response accuracy. This enables clinical pharmacologists to align drug design with the microbiome, serving pharmaceutical companies and clinical researchers focused on drug development and personalized medicine globally, especially in North America and Europe. Anto Biosciences generates revenue through partnerships with pharmaceutical companies and research institutions, structured as service agreements and collaborations.

These arrangements allow access to Anto's computational models and datasets for a fee, likely varying based on the complexity of the analysis needed, ensuring tailored insights into drug efficacy across different populations. In December 2025, a strategic investment was made in Anto Biosciences by multiple firms, including SBI Holdings and Line Corporation, to support its growth in the AI field and explore new business opportunities. Future plans include leveraging this investment to enhance product offerings and possibly expand into new markets, although specific new products or geographic regions targeted for expansion have not been disclosed.